169 related articles for article (PubMed ID: 34504551)
1. Antiproliferative therapy with sirolimus and propranolol for congenital vascular anomalies in newborns (Case reports).
Cîrstoveanu C; Bizubac AM; Mustea C; Manolache Ș; Istrate-Bârzan A; Sfrijan D; Marcu V; Iozsa DA; Spătaru RI
Exp Ther Med; 2021 Oct; 22(4):1097. PubMed ID: 34504551
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus for the treatment of children with various complicated vascular anomalies.
Lackner H; Karastaneva A; Schwinger W; Benesch M; Sovinz P; Seidel M; Sperl D; Lanz S; Haxhija E; Reiterer F; Sorantin E; Urban CE
Eur J Pediatr; 2015 Dec; 174(12):1579-84. PubMed ID: 26040705
[TBL] [Abstract][Full Text] [Related]
3. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
4. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
5. A not so harmless mass: Kaposiform hemangioendothelioma complicated by a Kasabach-Merritt phenomenon.
Tribolet S; Hoyoux C; Boon LM; Cheruy C; Demarche M; Jamblin P; Roberti A; Willemaers V; Viellevoye R; Rigo V; Broux I
Arch Pediatr; 2019 Sep; 26(6):365-369. PubMed ID: 31353149
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate.
Cabrera TB; Speer AL; Greives MR; Goff DA; Menon NM; Reynolds EW
AJP Rep; 2020 Oct; 10(4):e390-e394. PubMed ID: 33214934
[TBL] [Abstract][Full Text] [Related]
7. Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies-Insights From a Retrospective Case Series.
Karastaneva A; Gasparella P; Tschauner S; Crazzolara R; Kropshofer G; Modl M; Pfleger A; Burmas A; Pocivalnik M; Ulreich R; Zenz W; Schwinger W; Beqo BP; Urban C; Haxhija EQ; Lackner H; Benesch M
Front Pediatr; 2022; 10():857436. PubMed ID: 35676905
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
9. [Benign aggressive vascular anomalies in children].
Boccara O; Maruani A; Léauté-Labrèze C
Bull Cancer; 2018 Jun; 105(6):610-625. PubMed ID: 29571951
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
11. [Our experience with sirolimus for the treatment of complicated vascular anomalies].
Giménez-Aleixandre C; Méndez-Aguirre NA; Martínez-Menchón T; Girón Vallejo Ó; Fernández-Ibieta M; Ferri-Ñíguez B; Villamil V; Sánchez-Sánchez Á; Montoya-Rangel CA; Hernández-Bermejo JP
Cir Pediatr; 2019 Jan; 32(1):28-33. PubMed ID: 30714698
[TBL] [Abstract][Full Text] [Related]
12. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
[TBL] [Abstract][Full Text] [Related]
13. Use of Sirolimus in a Premature Neonate With Kaposiform Hemangioedema.
Koury J; Brown M; Sturtevant S; Wiley C; Felton L
J Pediatr Pharmacol Ther; 2021; 26(2):205-209. PubMed ID: 33603586
[TBL] [Abstract][Full Text] [Related]
14. [Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
Zhang GL; Gao Y; Liu Y; Gu F; Su W; Qin Q; Chen JY; Zhang HH; Yang J; Liu XY
Zhonghua Er Ke Za Zhi; 2017 Sep; 55(9):700-704. PubMed ID: 28881518
[No Abstract] [Full Text] [Related]
15. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
16. Laryngomalacia and complicated, life-threatening mTOR-positive Kaposiform hemangioendothelioma cured by Supraglottoplasty and sirolimus.
Schroeder U; Lauten M; Stichtenoth G; Gebhard MP; Buchholz M; Kaiser MM
Klin Padiatr; 2014 Nov; 226(6-7):362-8. PubMed ID: 24810750
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic study of pediatric vascular anomalies: a report of 117 cases].
Niu HL; Zhou SY; Lin QQ; Yi P; Wang FH; Gao Q; Chen ZR; Xia JQ; Zheng HC; Zeng RX
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):252-7. PubMed ID: 27033389
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
19. Angiopoietins as serum biomarkers for lymphatic anomalies.
Le Cras TD; Mobberley-Schuman PS; Broering M; Fei L; Trenor CC; Adams DM
Angiogenesis; 2017 Feb; 20(1):163-173. PubMed ID: 27990590
[TBL] [Abstract][Full Text] [Related]
20. A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas.
Ying H; Qiao C; Yang X; Lin X
Pediatrics; 2018 Apr; 141(Suppl 5):S425-S429. PubMed ID: 29610165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
